This company sold off because they said they were cutting 54% of their workers to help with cash flow into 2022 during the coronavirus pandemic. The market has clearly priced that in, and I honestly think it's long term bullish! Less employees: less people to pay out! CRBP has a lot of potential upside (more than likely not anytime soon), however, they have the 1st potential systematic sclerosis therapy that is looking to receive FDA approval some time around 2021 . Estimated revenue projections for the therapy, which would meet a need created by 320,000 patients worldwide if/when approved, are at 8 billion dollars. With only phase 2 data CRBP was able to get a deal from japan to close a deal for 27M (about 37,000 patients there). CRBP says they are trying to get the EU, and the rest of the globe for that matter, on board; If the EU was to grant a deal similar to Japans deal (made in 2018 btw), they could receive 233 million for that deal. All of this data is from a seeking alpha article; at 7 dollars they said the company has 2x upside from there. In all honesty I suspect to see a buyout in about 6 months or so... just a feeling; this stock is giving me an 'AIMT' vibe.
GL!